DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec SE to announce results for the first quarter 2021 on 11 May 2021
2021-05-04 / 11:30
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Hamburg, Germany, 04 May 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the
first quarter of 2021 on Tuesday, 11 May 2021.
The Company is going to hold a conference call to discuss the results as well as to provide an update on its
performance. The conference call will be held in English.
Conference call details
Date: Tuesday, 11 May 2021
Time: 02.00 pm CET (08.00 am EST, 01.00 pm GMT)
From Germany: +49 69 20 17 44 220
From France: +33 170 709 502
From Italy: +39 023 600 6663
From UK: +44 20 3009 2470
From USA: +1 877 423 0830
Access Code: 94660964#
A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/
evotec20210511/no-audio.
Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com
shortly before the event.
A replay of the conference call will be available for seven days and can be accessed from Germany by dialling +49 69
201744221, from UK by dialling +44 20 3364 5150 and from USA by dialling +1 (844) 307-9362.
The access code is 315614523#. The on-demand version of the webcast will be available on our website: https://
www.evotec.com/financial-reports.
ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative
product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and
venture capitalists. We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and
integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the
industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has
established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies
as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and
complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare
diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned
product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple
long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo
Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us
on Twitter @Evotec.
FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this
press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any such statement is based.
=----------------------------------------------------------------------------------------------------------------------
2021-05-04 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
=----------------------------------------------------------------------------------------------------------------------
Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf,
Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1192318
End of News DGAP News Service
=------------
1192318 2021-05-04
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1192318&application_name=news
(END) Dow Jones Newswires
May 04, 2021 05:31 ET (09:31 GMT)